Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya

This implementation study evaluated the health systems feasibility, economic costs, and stakeholder acceptability of deploying multiple first-line therapies (MFTs) that were of the artemisinin-based combination therapies (ACTs) type, for uncomplicated malaria in Western Kenya. The study included a nested observational molecular surveillance of antimalarial resistance markers in Plasmodium falciparum parasites. The implementation program involved adaptive cycling of four ACTs across 28 health facilities over 28 months (June 2020 - October 2022) with and extension to January 2024 in one geographic area (Mfangano Island). Health systems outcomes (feasibility, costs, acceptability) are reported in Cole et al., Malaria Journal 2024. Molecular surveillance outcomes (resistance marker prevalence and temporal trends) are reported in a companion manuscript currently under peer-review.

NCT Number	NCT07362498
Lead Sponsor	Strathmore University Collaborators: Medicines for Malaria Venture, KEMRI-Wellcome Trust Collaborative Research Program, Kenya Ministry of Health, National Malaria Control Program, Homa Bay County Government, Kenya, Migori County Government, Kenya, Kenya Medical Supplies Authority (KEMSA), Kenya
Conditions	Malaria Falciparum
Enrollment	316 participants
Start Date	2020-06-01
Primary Completion	2024-01-31 (estimated)
Study Completion	2024-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-23